Mark M. Pomerantz

9.4k total citations
114 papers, 3.2k citations indexed

About

Mark M. Pomerantz is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Mark M. Pomerantz has authored 114 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Pulmonary and Respiratory Medicine, 38 papers in Molecular Biology and 32 papers in Cancer Research. Recurrent topics in Mark M. Pomerantz's work include Prostate Cancer Treatment and Research (79 papers), Prostate Cancer Diagnosis and Treatment (26 papers) and Cancer, Lipids, and Metabolism (19 papers). Mark M. Pomerantz is often cited by papers focused on Prostate Cancer Treatment and Research (79 papers), Prostate Cancer Diagnosis and Treatment (26 papers) and Cancer, Lipids, and Metabolism (19 papers). Mark M. Pomerantz collaborates with scholars based in United States, Canada and Hungary. Mark M. Pomerantz's co-authors include Philip W. Kantoff, Matthew L. Freedman, William Oh, Wanling Xie, Meredith M. Regan, Mari Nakabayashi, Myles Brown, Gwo‐Shu Mary Lee, Robert W. Ross and Christopher J. Sweeney and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Mark M. Pomerantz

108 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark M. Pomerantz United States	30	1.9k	1.4k	1.0k	660	597	114	3.2k
Harold Keer United States	21	1.2k 0.6×	1.3k 0.9×	610 0.6×	627 0.9×	338 0.6×	75	2.6k
Mary-Ellen Taplin United States	30	2.3k 1.2×	646 0.5×	770 0.7×	672 1.0×	566 0.9×	42	3.1k
Toshinari Yamashita Japan	24	1.6k 0.8×	1.3k 0.9×	1.1k 1.1×	1.9k 2.9×	292 0.5×	135	3.7k
Timothy Eisen United Kingdom	10	2.0k 1.0×	1.8k 1.3×	1.0k 1.0×	949 1.4×	285 0.5×	17	3.5k
Tracy Curley United States	24	1.3k 0.7×	1.7k 1.2×	395 0.4×	1.1k 1.7×	172 0.3×	51	3.3k
Mario Giuliano Italy	34	1.2k 0.6×	1.0k 0.7×	1.4k 1.4×	2.4k 3.7×	351 0.6×	109	3.8k
Hiroyoshi Doihara Japan	29	513 0.3×	1.4k 1.0×	710 0.7×	1.4k 2.1×	332 0.6×	161	3.1k
Antonio Hurtado‐Coll Canada	24	1.2k 0.6×	887 0.6×	608 0.6×	349 0.5×	133 0.2×	39	2.0k
Tiffany A. Traina United States	30	1.4k 0.7×	1.1k 0.8×	1.6k 1.5×	2.4k 3.6×	698 1.2×	146	4.0k
Isabel Heidegger Austria	26	1.2k 0.6×	829 0.6×	554 0.5×	553 0.8×	118 0.2×	123	2.4k

Countries citing papers authored by Mark M. Pomerantz

Since Specialization

Citations

This map shows the geographic impact of Mark M. Pomerantz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark M. Pomerantz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark M. Pomerantz more than expected).

Fields of papers citing papers by Mark M. Pomerantz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark M. Pomerantz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark M. Pomerantz. The network helps show where Mark M. Pomerantz may publish in the future.

Co-authorship network of co-authors of Mark M. Pomerantz

This figure shows the co-authorship network connecting the top 25 collaborators of Mark M. Pomerantz. A scholar is included among the top collaborators of Mark M. Pomerantz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark M. Pomerantz. Mark M. Pomerantz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Yiwen, Konrad H. Stopsack, Adam S. Kibel, et al.. (2025). Identifying Patients at Risk of Early Lethal Prostate Cancer by Integrating Family History, Polygenic Risk Score, Rare Variants in DNA Repair Genes, and Lifestyle Factors. European Urology Oncology. 1 indexed citations

Ryan, Charles J., Arjun Gupta, Christopher J. Sweeney, et al.. (2025). Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial. European Urology Oncology.

Clark, Travis, John Canniff, Renée Maria Saliby, et al.. (2025). Epigenomic profiling of circulating chromatin for early detection and monitoring of neuroendocrine prostate cancer.. Journal of Clinical Oncology. 43(5_suppl). 253–253.

Ravi, Praful, Wanling Xie, Himisha Beltran, et al.. (2024). Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer. European Urology Oncology. 8(3). 709–715. 1 indexed citations

Stopsack, Konrad H., Joseph Vijai, Jacob E. Berchuck, et al.. (2024). Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer. Clinical Cancer Research. 31(1). 122–129. 5 indexed citations

Choudhury, Atish D., Hyewon Hyun, Emma Kelly, et al.. (2024). Patient outcomes after therapy with ¹⁷⁷Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC): A tertiary center experience.. Journal of Clinical Oncology. 42(4_suppl). 87–87. 1 indexed citations

Linder, Simon, Tesa Severson, Ekaterina Nevedomskaya, et al.. (2023). Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor–driven Programs. European Urology. 84(5). 455–460. 3 indexed citations

Qiu, Xintao, Lisha G. Brown, Holly M. Nguyen, et al.. (2022). Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome. JCI Insight. 7(10). 15 indexed citations

Guo, Haiyang, Yiming Wu, Mannan Nouri, et al.. (2021). Androgen receptor and MYC equilibration centralizes on developmental super-enhancer. Nature Communications. 12(1). 7308–7308. 42 indexed citations

10.

Penney, Kathryn L., Svitlana Tyekucheva, Jacob Rosenthal, et al.. (2020). Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. Molecular Cancer Research. 19(3). 475–484. 28 indexed citations

11.

Sztupinszki, Zsófia, Miklós Dióssy, Marek Krzystanek, et al.. (2020). Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations. Clinical Cancer Research. 26(11). 2673–2680. 56 indexed citations

12.

Rasool, Reyaz ur, Ramakrishnan Natesan, Qu Deng, et al.. (2019). CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. Cancer Discovery. 9(11). 1538–1555. 86 indexed citations

13.

McKay, Rana R., Dominick Bossé, Kathryn P. Gray, et al.. (2018). Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clinical Cancer Research. 24(17). 4081–4088. 26 indexed citations

14.

Hamid, Anis, Kathryn P. Gray, Ying Huang, et al.. (2018). Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. European Urology Oncology. 2(5). 475–482. 19 indexed citations

15.

Sun, Tong, William Oh, Susanna Jacobus, et al.. (2011). The Impact of Common Genetic Variations in Genes of the Sex Hormone Metabolic Pathways on Steroid Hormone Levels and Prostate Cancer Aggressiveness. Cancer Prevention Research. 4(12). 2044–2050. 24 indexed citations

16.

Pomerantz, Mark M., Lillian Werner, Wanling Xie, et al.. (2011). Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality. Cancer Prevention Research. 4(5). 719–728. 32 indexed citations

17.

Pomerantz, Mark M. & Matthew L. Freedman. (2011). The Genetics of Cancer Risk. The Cancer Journal. 17(6). 416–422. 42 indexed citations

18.

Whitman, Eric J., Mark M. Pomerantz, Yongmei Chen, et al.. (2010). Prostate Cancer Risk Allele Specific for African Descent Associates with Pathologic Stage at Prostatectomy. Cancer Epidemiology Biomarkers & Prevention. 19(1). 1–8. 29 indexed citations

19.

Penney, Kathryn L., Claudia A. Salinas, Mark M. Pomerantz, et al.. (2009). Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality. Clinical Cancer Research. 15(9). 3223–3230. 42 indexed citations

20.

Ross, Robert W., William Oh, Wanling Xie, et al.. (2008). Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate Cancer. Journal of Clinical Oncology. 26(6). 842–847. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact